oryzacody.wordpress.com
The partnership, meant to discover, develop and and commercializ e RNAi-based therapeutics toward a defined numberof Novartis-selectesd disease gene targets, is now set to run throughu Oct. 2010. Cambridge-based Alnylaj (Nasdaq: ALNY) said this will be the fiftg and final year of the This is the second time Alnylamj extended the partnershipwith Switzerland-based The deal with Novartis (NYSE: NVS) is worthj more than $700 million to Alnylam assuming their research leads to commercial Scientists believe that which occurs naturally within cells, can be harnessed to silencwe genes that cause disease.
With the extensionm of the alliance term, Novartias will continue to fund collaboration research and developmenty efforts conductedby Alnylam. Further, Novartiss retains certain rights to purchased Alnylam equity up to its currentownership level, whic is approximately 13.4 percent.
No comments:
Post a Comment